Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

Q: What is the clinical evidence from this study?

Study design: Review. Population: Valvular heart disease (aortic stenosis, aortic regurgitation, mitral regurgitation, mitral stenosis). Intervention: Natriuretic peptides (BNP, NT-pro-BNP, ANP) vs. Standard echocardiographic and clinical assessment.

Abhishek Sharma; Vaseem Ahmed; Aakash Garg; Chirag Aggarwal

doi:10.1155/2015/807861

January 1, 2015Disease MarkersOpen Access

Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

View Full Paper

Ask AI

Bookmark

Share

Key result

Natriuretic peptides correlate with severity and independently predict prognosis in asymptomatic significant valvular heart disease.

Why the study?

What is the role of natriuretic peptides in the assessment, risk stratification, and monitoring of patients with valvular heart disease?

Key Points

Examine the clinical evidence for utilizing natriuretic peptides to evaluate, risk-stratify, and monitor patients with valvular heart disease.
Narrative review evaluating clinical applications of atrial natriuretic peptide, B-type natriuretic peptide (BNP), and N-terminal pro-BNP in valvular heart disease management.
Synthesis of evidence across disease severity assessment, ventricular remodeling, post-intervention outcomes, and biological or assay confounders.
Circulating natriuretic peptide concentrations correlate positively with aortic stenosis severity, left ventricular hypertrophy, and wall stress, and negatively with left ventricular ejection fraction.
Serum BNP above 66 pg/mL demonstrated utility in differentiating symptomatic from asymptomatic severe aortic stenosis, while post-TAVR increases in 30-day BNP were significantly associated with higher one-year mortality.
Biomarker interpretation is influenced by clinical factors including age, renal function, and obesity, typically requiring individual changes of 25% for NT-pro-BNP and 40% for BNP to indicate true hemodynamic shifts.

Structured PICO

What is the role of natriuretic peptides in the assessment, risk stratification, and monitoring of patients with valvular heart disease?

P

Population

Patients with stenotic or regurgitant valvular heart disease, particularly asymptomatic patients with hemodynamically significant valvular lesions evaluated across reviewed studies.

E

Exposure

Assessment using natriuretic peptides (NPs)

Natriuretic peptides may provide valuable prognostic and monitoring information in patients with valvular heart disease, complementing echocardiographic data and functional status.

Limitations

Natriuretic peptide levels are confounded by non-valvular conditions such as renal dysfunction, advanced age, female sex, atrial fibrillation, acute coronary syndromes, lung disease, and obesity.
Coexisting multiple valvular lesions can cause further elevation of natriuretic peptides and confound interpretation.
Intra-assay precision coefficient of variation for commonly used BNP assays ranges from 5% to 15%.
Significant biological variation exists both between individuals and within the same individual (requiring changes of 25% for NT-pro-BNP and 40% for BNP to reflect clinically significant volume changes).

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May aid risk stratification in asymptomatic valvular disease; leaves open whether monitoring changes management or outcomes.

Abstract

Biomarkers such as natriuretic peptides (NPs) have evolving clinical utility beyond the scope of heart failure. The role of NPs in the management of valvular heart disease is a growing area of investigation. NPs have much potential in the assessment of asymptomatic patients with hemodynamically significant valvular lesions who have traditionally been excluded from consideration of surgical intervention. NPs also have a role in the risk stratification of these patients as well as in routine surveillance and monitoring. Together with echocardiographic data and functional status, NPs are being incorporated into the management of valvular heart disease. In this review we examine the evidence for the role of natriuretic peptides in assessment of VHD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sharma et al. (2015) conducted a review in Valvular heart disease (aortic stenosis, aortic regurgitation, mitral regurgitation, mitral stenosis). Natriuretic peptides (BNP, NT-pro-BNP, ANP) vs. Standard echocardiographic and clinical assessment was evaluated. Natriuretic peptides (BNP and NT-pro-BNP) correlate with lesion severity and provide independent prognostic risk stratification in asymptomatic patients with hemodynamically significant valvular heart disease.

synapsesocial.com/papers/6a7c8eb32bc3e5689c4c7156 https://doi.org/10.1155/2015/807861

View Full Paper

Ask AI

Bookmark

Share

Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading